Stoke Therapeutics, Inc. STOK Proceeds From Controlled Equity Offering Sales Agreement Net Of Commissions
Proceeds From Controlled Equity Offering Sales Agreement Net Of Commissions at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept stok:ProceedsFromControlledEquityOfferingSalesAgreementNetOfCommissions.
The official record: Stoke Therapeutics, Inc.’s 10-K, filed March 16, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s proceeds from controlled equity offering sales agreement net of commissions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s proceeds from controlled equity offering sales agreement net of commissions?
- Stoke Therapeutics, Inc. (STOK) reported proceeds from controlled equity offering sales agreement net of commissions of $21.95M in Q4 2025.
- How has Stoke Therapeutics, Inc.'s proceeds from controlled equity offering sales agreement net of commissions changed year-over-year?
- Stoke Therapeutics, Inc.'s proceeds from controlled equity offering sales agreement net of commissions increased by 880.2% year-over-year, from $2.24M to $21.95M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s proceeds from controlled equity offering sales agreement net of commissions?
- Over 2 years (2023 to 2025), Stoke Therapeutics, Inc.'s proceeds from controlled equity offering sales agreement net of commissions has grown at a 29.8% compound annual growth rate (CAGR), from $52.08M to $87.78M.
- What does proceeds from controlled equity offering sales agreement net of commissions mean?
- This represents the net cash proceeds received from the sale of equity securities through an 'at-the-market' or controlled equity offering program. It serves as a flexible financing mechanism for companies to raise capital incrementally without the market impact of a large, singular offering. Investors view this as a key indicator of the company's ability to access capital markets to fund ongoing research and development.